[Morvan syndrome associated with unresectable thymoma responsive to chemotherapy: a case report].
Morvan syndrome
chemotherapy
parasomnia
thymoma
voltage-gated potassium channel (VGKC)-complex antibodies
Journal
Rinsho shinkeigaku = Clinical neurology
ISSN: 1882-0654
Titre abrégé: Rinsho Shinkeigaku
Pays: Japan
ID NLM: 0417466
Informations de publication
Date de publication:
27 Aug 2022
27 Aug 2022
Historique:
pubmed:
25
7
2022
medline:
31
8
2022
entrez:
24
7
2022
Statut:
ppublish
Résumé
A 51-year-old Japanese man presenting with a several-month history of parasomnia, orthostatic hypotension and generalized myokymia was admitted to our hospital. He had a past medical history of unresectable recurrent thymoma, but chemotherapy for thymoma was discontinued according to the patient's decision four years before this hospitalization, and the thymoma had enlarged. He exhibited symptoms of the peripheral nervous system (myokymia), central nervous system (parasomnia, short-term memory impairment), and autonomic nervous system (orthostatic hypotension), and his serum was positive for voltage-gated potassium channel (VGKC)-complex antibodies. Based on the above findings, Morvan syndrome was diagnosed. Resumption of chemotherapy for thymoma resulted in shrinkage of the thymoma accompanied by remission of Morvan syndrome. Subsequently, discontinuation of chemotherapy led to aggravation of thymoma with recurrence of Morvan syndrome. This clinical course suggests a strong correlation between the disease activity of thymoma and Morvan syndrome. In the present case of Morvan syndrome associated with unresectable thymoma, chemotherapy contributed to the remission of Morvan syndrome. Our patient suggests a possibility that chemotherapy for thymoma is a useful treatment for Morvan syndrome.
Identifiants
pubmed: 35871563
doi: 10.5692/clinicalneurol.cn-001729
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Case Reports
Journal Article
Langues
jpn
Sous-ensembles de citation
IM